NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, THE UNITED KINGDOM, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH OR NORWEGIAN LAW.
Genetic Analysis AS (“GA” or the “Company”) announced on November 2, 2023, and November 3, 2023, that the Board of Directors of GA had successfully placed and conditionally allocated in total of 13,283,007 new shares at a subscription price of NOK 0.79 per share (the “Directed Issue”). The Company, moreover, announced on November 2, 2023, the intention to conduct a Subsequent Offering with preferential right for shareholders which have not been allocated shares in the Directed Issue (the “Subsequent Offering”). The correction refers to an updated intended record date for the intended Subsequent Offering stated in the press releases on November 2, 2023, and November 3, 2023. The intended record date is updated to on or about December 7, 2023 from previously November 6, 2023. The final date of the record date of the Subsequent Offering is subject to that the EGM grants an authorization to the Board of Directors, that such an authorization is registered with the Norwegian Register of Business Enterprises (“NRBE”) in due time and that it is used in connection with the Subsequent Offering and the time of such a decision by the Board of Directors.
The Company announced, on November 2, 2023, the intention to conduct a Subsequent Offering of up to approximately NOK 9 million and 11,392,405 shares with preferential right for shareholders which have not been allocated shares in the Directed Issue in order to reduce the dilution effect from the Directed Issue and to potentially raise additional financing (the “Subsequent Offering”).
The correction refers to an updated intended record date for the intended Subsequent Offering stated in the press releases on November 2, 2023, and November 3, 2023. The intended record date is updated to on or about December 7, 2023 from previously November 6, 2023 (as registered in Euronext Securities Oslo (formerly named VPS)). Hence, the last day of trading in the share, including subscription right in the Subsequent Offering, would be on or about December 5, 2023 and first day of trading in the share, excluding subscription right in the Subsequent Offering, would be on or about December 6, 2023.
The Subsequent Offering will be directed towards shareholders who (i) were not allocated shares in the Directed Issue and (ii) are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Sweden) require any prospectus, filing, registration or similar action. The final date of the record date of the Subsequent Offering is subject to that the EGM grants an authorization to the Board of Directors, that such an authorization is registered with the NRBE in due time and that it is used in connection with the Subsequent Offering and the time of such a decision by the Board of Directors.
Please read the full press release in English: